Navigation Links
Social bonding in prairie voles helps guide search for autism treatments
Date:4/28/2011

Researchers at the Center for Translational Social Neuroscience (CTSN) at Emory University are focusing on prairie voles as a new model to screen the effectiveness of drugs to treat autism.

They are starting with D-cycloserine, a drug Emory researchers have shown enhances behavioral therapy for phobias and also promotes pair bonding among prairie voles. Giving female voles D-cycloserine, which is thought to facilitate learning and memory, can encourage them to bond with a new male more quickly than usual.

The results are published online and will appear in a future issue of Biological Psychiatry.

"The prairie vole model has enabled us to learn about complex neural pathways in social areas of the brain," says senior author Larry Young, PhD. We believe these insights will be useful in identifying drugs that enhance social cognition and learning. Drugs with these properties, particularly when combined with behavioral therapies, may be beneficial in the treatment of autism spectrum disorders."

Young is division chief of Behavioral Neuroscience and Psychiatric Disorders at the Yerkes National Primate Research Center, William P. Timmie professor of psychiatry and behavioral sciences at Emory University School of Medicine and director of the Emory CTSN (www.ctsn.emory.edu).

He and his colleagues have been studying the prairie vole for more than 15 years as a model to explore the neurobiology of prosocial behaviors, including cooperation, compassion, bonding and social reciprocity. Now, they are hoping to identify drugs that can enhance social learning in individuals with autism spectrum disorders, and they think the process of pair bonding in the prairie vole may be a useful tool for identifying new therapies.

The prairie vole is one of the few species in nature that is monogamous and that creates deep social bonds while mating, Young says. The basic mechanisms of voles' and humans' social learning are similar enough that the learning that occurs during voles' pair bonding can model complex human social interactions, he says. Young and his colleagues have used voles to show the importance for social interactions of hormones such as oxytocin, which has also been proposed as a treatment for autism spectrum disorders.

The first author of the paper is Emory graduate student Meera Modi. She showed that D-cycloserine promotes pair bonding in prairie voles when it is injected peripherally. By infusing the drug directly into specific regions of the brain, she also showed the importance of two regions linked to social learning and reward, the nucleus accumbens and amygdala.

"We think D-cycloserine interacts with the brain's social information processing circuits to enhance the natural learning processes that occur there," Modi says.

With voles, the "partner preference paradigm" works like this: sexually nave females are placed with sexually experienced males for six hours of cohabitation. The females are not ovulating and no mating occurs. Normally, pair-bonding requires more time -- 24 hours -- and mating is necessary.

Later, the females are given a choice between spending time with the newly familiar male and a stranger; researchers then measure how much time they spend with each male over the next three hours. When a low dose of the drug D-cycloserine is injected at the start of cohabitation, the female prefers the familiar male by a factor of at least four. Without the drug, the female doesn't markedly prefer either male.

Emory researchers have shown D-cycloserine can be used to treat psychiatric diseases such as phobias and social anxiety. It is now in clinical trials for treatment of post-traumatic stress disorder. D-cycloserine is thought to enhance learning by acting on receptors for the neurotransmitter glutamate.

Autism spectrum disorders affect one in 110 children in the United States, according to the Centers for Disease Control and Prevention. Currently there are no drugs that specifically target social deficits found in individuals with autism, Young notes. Most drugs now prescribed for individuals with autism were originally developed for other disorders such as depression or schizophrenia.


'/>"/>

Contact: Holly Korschun
hkorsch@emory.edu
404-727-3990
Emory University
Source:Eurekalert

Related medicine news :

1. Social media can alter research priorities, according to paper in Nature
2. Higher levels of social activity decrease the risk of cognitive decline
3. Study links social environment to high attempted suicide rates among gay youth
4. Gene linked to severity of autisms social dysfunction
5. Social Media Has Good and Bad Effects on Kids: Experts
6. Social class makes no difference to water contamination risk
7. Image, Appearance Rank High Among Social Network Users
8. Chimps, Too, May Use Laughter for Social Gain
9. Experts explore vaccines: Science, legal, social issues at New York Academy of Sciences
10. Busy Social Life May Stave Off Disability in Elderly
11. Diabetes Social Networking Web Sites Vary in Quality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Coast Dental Fort Stewart ... at its new location in the Exchange Furniture Mall at 112 Vilseck Road in ... 50-inch Samsung Smart TV. Plus attendees will have the opportunity to meet general dentists ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Wharton ... $30,000 Perlman Grand Prize of the 2016 Wharton Business Plan Competition —as ... People’s Choice Award, and the Committee Award for Most ‘Wow Factor,’ making them ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Gluten-Free Certification Program ... to announce the launch of the GFCP Scoop in response to ... purpose of the GFCP Scoop site is to keep the gluten-free ...
(Date:4/29/2016)... ... April 29, 2016 , ... New York City based oral and maxillofacial surgeon Dr. ... very effective way to treat obstructive sleep apnea. Dr. Jamali is proud to offer this ... procedure that involves one or both jaw bones. This surgery is performed to correct the ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the ... of funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... base and accelerate its technology and product roadmap. , “Jvion is ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... April 28, 2016 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral drug delivery ... upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... New York . Nadav Kidron , ... conference. Presentation Details:   PIONEERS ...
(Date:4/27/2016)... -- Hologic, Inc. (Nasdaq: HOLX ) announced ... second quarter ended March 26, 2016.  GAAP diluted ... and non-GAAP diluted EPS of $0.47 increased 14.6%.  ... reported basis, and 6.3% on a constant currency ... quarter, highlighted by 14.6% growth in non-GAAP EPS," ...
(Date:4/27/2016)... York , April 27, 2016 ... report titled, "Skincare Devices Market - Global Industry Analysis, ... According to the report, the global skincare devices market ... is anticipated to expand at a CAGR of 10.1% ... in 2023. Browse the full Skincare Devices Market ...
Breaking Medicine Technology: